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Abstract Cone snails are marine predators that use venoms
to immobilize their prey. The venoms of these mollusks
contain a cocktail of peptides that mainly target different
voltage- and ligand-gated ion channels. Typically, cono-
peptides consist of ten to 30 amino acids but conopeptides
with more than 60 amino acids have also been described.
Due to their extraordinary pharmacological properties,
conopeptides gained increasing interest in recent years.
There are several conopeptides used in clinical trials and
one peptide has received approval for the treatment of pain.
Accordingly, there is an increasing need for the production
of these peptides. So far, most individual conopeptides are
synthesized using solid phase peptide synthesis. Here, we
describe that at least some of these peptides can be obtained
using prokaryotic or eukaryotic expression systems. This
opens the possibility for biotechnological production of
also larger amounts of long chain conopeptides for the use
of these peptides in research and medical applications.
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Introduction
Cone snails are mainly known due to the beauty of their
shells, which can be found in plenty of the “sea side
souvenir shops” all over the world. Commonly not so well
recognized is that the biology of these marine snails is very
fascinating because these slow animals live as predators.
All of the about 500 species known do hunt animals, e.g.,
other snails, worms, or even fish (see Fig. 1). The
immobilization of the prey results from the action of
relative complex venoms, which are injected into the
victims by using harpoon like teeth. The venom of each
species contains up to 200 pharmacologically active
components that mainly target different voltage- and
ligand-gated ion channels (for overviews see: Olivera et
al. 1990; Olivera 2002; Terlau and Olivera 2004). With
respect to the venom action on the victim, the different
conopeptides can be grouped according to their biological
role for the immobilization of prey (for more details see:
Olivera 1997). Some conopeptides have been shown to be
important for the fast immobilization of the prey (“lightning
strike cabal”) whereas others exert their action during later
phases of the envenomation, which results in an irreversible
block of neuromuscular transmission (“motor cabal”).
Because of their special pharmacological properties con-
opeptides have gained increasing interest in recent years.
Moreover, since several conopeptides are currently being
tested within clinical trials and the ω-conotoxin MVIIA has
obtained an approval as an analgesic drug (Ziconitide,
Prialt®) there is an increasing need to produce conopeptides
in larger quantities.
In this review, we briefly describe the properties of
conopeptides and discuss the current and potential applica-
tions of conopeptides in research and clinics. Furthermore,
we describe ways of biotechnological production of these
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Properties of conopeptides
Conopeptides are genetically encoded small proteins that
are initially translated as prepropeptide precursors consist-
ing of a signal sequence (the “pre” region) followed by a
“pro” region, and at the C-terminal part representing the
mature toxin region. The pharmacological active peptide is
generated by an enzymatic cleavage of the C-terminal part
of the prepropeptide. With respect to their amino acid
sequence, conopeptides can be classified in two broad
classes: the disulfide-rich peptides and the non-disulfide-
rich peptides (Terlau and Olivera 2004).
For the disulfide-rich peptides, several superfamilies
have been defined according to the difference in their
cysteine connectivity. Within these superfamilies, different
peptides may have different targets. Therefore, a given
superfamily may consist of several conotoxin families
grouped according to their pharmacological properties.
The targets of conopeptides are usually voltage-gated and
ligand-gated ion channels. For example, within the O-
superfamily of disulfide-rich conopeptides that contain six
cysteines with an arrangement also known from peptides of
different origins (the “inhibitor cystine knot” motif), at least
four different families have been identified: the δ-conotox-
ins, known to inhibit the fast inactivation of voltage-gated
Na
+ channels, the μO-conotoxins that inhibit voltage-gated
Na
+ currents, the κ-conotoxins which interact with voltage-
gated K
+ channels, and the ω-conotoxins known to block
voltage-activated Ca
++ channels. In terms of the immobili-
zation of prey, the peptides from these different families can
be involved in the lightning strike cabal or in the motor
cabal. For the fish hunting species, Conus purpurascens,
for example, it has been shown that the δ-conotoxins PVIA
and the κ-conotoxin PVIIA are crucial for the lightning
strike cabal (Terlau et al. 1996).
One of the most striking features of conopeptides is their
pharmacological properties: conopeptides are known to be
extraordinarily potent and highly specific. The ω-conotoxin
MVIIA, for example, specifically targets N-Type Ca
++
channels (Cav2.2) with little affinity to other Ca
++ channel
subtypes (Olivera et al. 1987; Hillyard et al. 1992). Since
N-type Ca
++ channels are primarily located in the presyn-
aptic space, the action of ω-conotoxin MVIIA results in
blocking synaptic transmission and therefore during enve-
nomation of prey, this peptide is involved in the motor
cabal. With respect to the action of the whole venom, the
extraordinary specificity of the conopeptides indicates that
every single peptide is a “specialist” optimized for a certain
target and that only the concerted action of the different
peptides present in the venom results in the biological
action needed for the achievement of the predatory life of
these snails. Due to these pharmacological properties,
conopeptides can be ideal tools to study the structure and
function of a given target (see below). The finding that
peptides with similar cysteine connectivity target different
Fig. 1 Conus purpurascens
hunting a clown fish. The snail
stings the fish with a harpoon
like tooth, which is hollow and
barbed and held at the tip of the
proboscis. Upon venom injec-
tion (upper right) the fish is
immobilized within less than a
few seconds (lower left) and
engulfed by the snail (lower
right; originally from Terlau et
al. 1996)
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changes in the overall structure of these peptides can result
in major pharmacological differences. In fact, these prop-
erties might help for the understanding of pharmacological
specificity for ion-channel subtypes (i.e., K
+ channel vs.
Na
+ channel).
Investigations on the venom composition of cone snails
suggest that during evolution, every single species of cone
snails has developed its own set of conopeptides and it has
been estimated that probably more than 50,000 different
conopeptides can be found in the venoms of all cone snail
species (Terlau and Olivera 2004). Accordingly, conopep-
tides are extremely variable in their amino acid sequences
and the pharmacological properties of only a few of these
conopeptides have been characterized in detail so far. The
current idea on how the snails have evolved these highly
specific peptides within their 50 million years of evolution
is that for the cysteine-rich peptides, a hypermutation has
occurred for the amino acids in between these cysteines of
the mature toxin. Interestingly, in contrast to the mature
toxin, the signal sequence of the precursor peptides within a
superfamily gene is highly conserved (Olivera 1997, 2006).
This high degree of homology can be used for the
identification of new peptides from the same family by
using PCR techniques.
For the biological function of the cysteine-rich peptides,
their disulfide bridges are known to be essential. Further-
more, the disulfide bridges represent a backbone for the
structure of these peptides, which are usually relatively
stable. The structure of several conopeptides has been
solved either by NMR or X-ray analysis.
A striking feature of conopeptides is the presence of a
variety of posttranslational modifications, which include
hydroxylation of prolines, carboxylation of glutamate, D-
amino acids, or sulfated tyrosine (Buczek et al. 2005).
There are indications that cone snails express the enzymes
important for those modifications in their venom ducts
(Stanley et al. 1997; Bandyopadhyay et al. 1998). For γ-
carboxylation, it was shown that the enzyme has a
recognition signal in the pro region of the precursor. The
functional importance of these posttranslational modifica-
tions is only partially understood but for the biotechnolog-
ical production of conopeptides, these modifications
introduce some limitations (see below).
Applications of conopeptides
The extraordinary pharmacological specificity of conopep-
tides resulted in an intensive use of these peptides for
different applications. The ω-conotoxins, for example, are
heavily used in neuroscience and also in other areas of
research to study the function of Ca
++-channel subtypes.
Accordingly, for the most widely used ω-conotoxin, GVIA,
there are about 2,000 research papers published using this
peptide as a tool to study these channels.
Due to their specific binding properties, conopeptides
can also be valuable tools to obtain structural information
about their corresponding target. Especially for transmem-
brane proteins where no or little structural information is
available, the interaction of peptidic toxins can be used to
gain structural information of the target protein by using the
interaction surface of the peptide as a fingerprint of the
interaction surface of the target. Besides conopeptides, also
specific toxins from other organisms like scorpions or
snakes are used for these studies which have paved the way
for obtaining the first structural data on K
+ channels (Miller
1995; Doyle et al. 1998; MacKinnon et al. 1998).
Interestingly, most recent data obtained by solid-state
NMR suggest that obviously during the binding of peptide
toxins to their target, some conformational changes on both
binding partners occur (Lange et al. 2006). These results
indicate that at least some conformational dynamics take
place during drug–target interactions.
Since voltage-gated and ligand-gated ion channels as the
target proteins of conopeptides are involved in a variety of
different physiological functions, it becomes immediately
clear that certain conopeptides do have the potential to act
as lead compounds for new drugs. Accordingly, several
conopeptides are currently undergoing clinical trials. Since
the application of peptides as drugs is limited it is clear that
not always the actual peptide will be the substance of
choice for a given indication. But nevertheless, these
peptides will help our understanding in how substances do
interact with their target and maybe, thereby, opening new
fields of pharmaceutical research.
The first example of a conopeptide that is used as a drug is
ω-conotoxinMVIIA(Ziconitide,Prialt®)fromConus magus,
which has been approved for the treatment of intractable pain
(Miljanich 2004;S t a a t se ta l .2004; Stix 2005). Interestingly,
ω-conotoxin MVIIA is one of the first substances from a
marine organism that became a drug used in clinics.
Several other conopeptides are currently being explored
as antinociceptive agents. The analgesic effect can be
mediated through the interaction with different targets
including voltage-activated Ca
++ channels and Na
+ chan-
nels but also nicotinic acetylcholine receptors, neurotensin
receptors, NMDA-type glutamate receptors, and norepi-
nephrine transporter (Olivera 2006). This demonstrates that
the specific action of conopeptides can interfere within
different signaling pathways involved in pain sensation. In
addition, the analgetic action of these peptides helps in the
understanding of the molecular mechanisms involved in
pain. Only through the discovery that ω-conotoxins are
analgetic, for example, did it become clear that N-Type Ca
++
channels are a potential drug target for severe pain.
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be useful for other clinical indications. For κ-conotoxin
PVIIA (see Fig. 2), for example, it has been demonstrated
that it reduces the size of the myocardial infarct in an
ischemia/reperfusion model in rabbits, rats, and dogs in
vivo (Zhang et al. 2003; Lubbers et al. 2005). An important
feature of this cardioprotective effect is that the reduction
was not only observed when κ-PVIIA was applied prior to
ischemia, but also if given after the ischemic event and
prior to reperfusion, which reflects more the clinical
situation.
These examples demonstrate that the biomedical poten-
tial of conopeptides is established and that it is very likely
that due to the current research on the characterization of
their properties, further conopeptides with very interesting
pharmacological properties will be discovered.
Biotechnological production of conopeptides
From the natural source, conotoxins can only be obtained in
tiny quantities that limit their availability for research and
medical applications. To obtain larger amounts of these
peptides, two basic approaches are available: chemical
synthesis and recombinant production in heterologous
expression systems (Fig. 3). Due to the posttranslational
modifications of many conotoxins described above (Craig
et al. 1999; Buczek et al. 2005), chemical synthesis via
solid phase peptide synthesis (SPPS) on a resin support
(Merrifield 1963) has been the method of choice to produce
conotoxins in large quantities. SPPS using the orthogonal
9-Fluorenylmethyloxycarbonyl (Fmoc)/tertiary-Butyl (tBu)
chemistry (Chang and Meienhofer 1978) allows the use of
piperidine and trifluoroacetic acid to remove the N-terminal
Fmoc and the side chain protection groups, respectively.
These low-hazard reagents allow the synthesis of peptides
also in typical biology lab environments, making SPPS
peptide synthesis available to many life scientists. After
removal of the protection groups and cleavage from the
resin, the linear peptide needs to be refolded to generate
the correct secondary and tertiary structure including the
formation of the correct disulfide bond pattern between the
cysteine residues present in the polypeptide chain. This
oxidation step is usually performed with molecular oxygen
(Rudolph and Lilie 1996). The yield of correctly formed
disulfide bonds in this step is usually low but can be
considerably increased by performing thiol-disulfide ex-
change reactions with low-molecular-weight thiols that are
added in reduced and oxidized form. Typical “oxido-
shuffling” reagents are the combinations of reduced and
oxidized glutathione, cysteine and cystine, cysteamine
and cystamine or di-β-hydroxyethyl disulfide, and 2-
mercaptoethanol (Rudolph and Lilie 1996; Bulaj 2005;
Lovelace et al. 2006). The thiol–disulfide exchange takes
place by nucleophilic attack of the thiolate anion. There-
fore, the folding reaction of the disulfide-rich conotoxin
peptides is usually performed at mildly alkaline conditions
(Moroder et al. 1996; Rudolph and Lilie 1996). SPPS is
Fig. 2 Sequence and structure of K
+ channel binding conotoxins.
Despite a different cysteine backbone and different structures all the
three peptides κ-PVIIA (pdb code: 1AV3); κM-RIIIK (*) and Conk-
S1 (pdb code: 2CA7) interact with Shaker K
+ channels by occluding
the ion channel pore (Shon et al. 1998; Jacobsen et al. 2000; Ferber et
al. 2003; Al-Sabi et al. 2004; Bayrhuber et al. 2005; Verdier et al.
2005). O 4-hydroxyproline; Z pyroglutamate; # denotes an amidated
C-terminal amino acid. * Structural coordinates obtained from T.
Carlomagno
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most known conotoxins consist of about 10–30 amino acid
residues (Terlau and Olivera 2004), SPPS is perfectly
suitable for their production. Classical examples for con-
otoxins synthesized by SPPS are the Ca
++-channel inhibitor
ω-Conotoxin GVIA (Rivier et al. 1987) and µ-Conotoxin
GIIIA (Becker et al. 1989), an inhibitor of voltage-
dependent Na
+ channels. Many other conotoxins with
posttranslationally modified amino acids have been suc-
cessfully produced by SPPS in the last 20years.
Chemical ligation of purified peptide fragments can be
used to produce longer polypeptides containing up to
several hundred amino acids (Dawson and Kent 2000).
Using this technique, Conkunitzin-S1 (Conk-S1; see Fig. 2)
was recently synthesized (Dy et al. 2006). This conopeptide
belongs to a new class of conotoxins that do not contain
posttranslational modifications apart from C-terminal ami-
dation and that are structurally strongly related to Kunitz
proteins (Bayrhuber et al. 2005; Dy et al. 2006). The
expenses for the chemicals and protected amino acids to
synthesize such large peptides are quite high. A cost-
effective alternative approach to produce such peptides in
larger quantities is the use of bacterial and eukaryotic
expression systems. The limited posttranslational machin-
ery of these expression systems does not permit the
production of peptides with the kind of posttranslational
modifications found in many smaller conopeptides (Craig
et al. 1999;B u c z e ke ta l .2005). Escherichia coli is the
best characterized and most widely used bacterial host
for the production of recombinant proteins (Baneyx
1999; Pines and Inouye 1999). The reasons are the low
costs for culturing E. coli and the short culturing times. In
general, small peptides are difficult to overexpress directly
in E. coli since they are either quickly degraded by cellular
proteases or they accumulate to form insoluble aggregates,
so-called inclusion bodies (Georgiou and Valax 1996). In
addition, the cytoplasm of E. coli is a reducing environ-
ment that prevents the formation of disulfide bonds (Prinz
et al. 1997), further increasing the tendency to form
inclusion bodies upon overexpression. To achieve at least
high expression levels of these small peptides, expressing
them in fusion with larger, well-expressing carrier proteins
has been the most successful approach so far (Butt et al.
1989; Malakhov et al. 2004). The use of highly soluble
carrier proteins like, e.g., maltose-binding protein (Kapust
and Waugh 1999), thioredoxin (Lavallie et al. 1993), or
glutathione S-transferase (Nygren et al. 1994) can even
lead to the expression of soluble fusion proteins. Through
affinity chromatography targeting such carrier proteins,
these soluble fusion proteins can often be easily purified
(Nygren et al. 1994; Esposito and Chatterjee 2006;P e t i
and Page 2007). The additional use of protease-deficient
host strains (Maurizi 1992;G o t t e s m a n1996) can help to
avoid non-specific proteolytic degradation. From the
refolded or soluble fusion protein, the peptide has to be
released by chemical or proteolytic cleavage at a pre-
engineered cleavage site located in the protein sequence
between the carrier protein and the target peptide sequence
(Esposito and Chatterjee 2006). Following this approach,
the medically important ω-conotoxin MVIIA (Ziconitide)
was produced in soluble form as a fusion protein with
glutathione S-transferase (Xia et al. 2006). Very recently,
the newly discovered Conotoxin lt7a was produced in
soluble form in fusion with thioredoxin (Pi et al. 2007).
When soluble expression can not be achieved, the
protein must be solubilized from the inclusion bodies
with denaturing reagents like urea and guanidinium
hydrochloride and subsequently refolded by dilution into
or by dialysis against a target buffer containing no
denaturant (Fahnert et al. 2004). Similar to the formation
Fig. 3 Ways to biotechnological production of disulfide-rich peptides.
Solid phase peptide synthesis of disulfide-rich peptides requires
subsequent folding of the peptide fragment in the presence of oxygen.
Addition of low-molecular-weight thiols in oxidized and reduced form
(oxido-shuffling reagents) to the folding solution can help to increase
the yield of correctly folded peptide. Recombinant peptide production
can result in insoluble protein (inclusion bodies) or soluble protein.
From inclusion bodies folding in the presence of oxido-shuffling
reagents can be successful
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above), the yield of this refolding step can often be
strongly increased by addition of oxido-shuffling reagents
(Rudolph and Lilie 1996). In this way, the recombinant
conopeptide Conk-S1 has been refolded (Bayrhuber et al.
2006; see also below).
Alternatively, strains with knocked-off oxidoreductases
like, e.g., E. coli Origami (Novagen) offer a moderately
oxidizing environment in their cytoplasm and can be used
to increase the fraction of correctly folded disulfide-bonded
proteins (Prinz et al. 1997). Although it seems that
expression levels tend to be low in such strains (Xiong et
al. 2005), this approach has been successfully used for
soluble expression of proteins with disulfide bonds (for
example, see Lauber et al. 2001; Lehmann et al. 2003;
Rabhi-Essafi et al. 2007). But a successful expression of
small disulfide-rich peptides like the conotoxins has not
been reported so far in such a strain.
Another possibility to obtain soluble fusion proteins of
disulfide-rich peptides is the expression into the oxidative
environment of the periplasm using a signal peptide
sequence in the expression construct. This approach has
been successfully used for the periplasmic expression of
dendrotoxins and scorpion toxins as fusion proteins with
maltose-binding protein (Ducancel et al. 1989; Legros et al.
1997; Legros et al. 2001). More recently, peptides with the
inhibitor cystine knot (ICK) structural motif have even been
successfully secreted into the culture medium by expressing
them as barnase fusion proteins (Schmoldt et al. 2005).
Periplasmic expression approaches have not been success-
fully used for the small disulfide-rich conotoxins. Oxidative
folding in the periplasmic space seems to work efficiently
only for specific disulfide bridge patterns.
In most fusion protein expression vectors with engi-
neered protease cleavage site, the cloning sites for the
peptide coding sequence are located downstream of the
coding sequence for the protease recognition site. There-
fore, the proteolytic release of peptides from their fusion
partner has the potential disadvantage that the cleaved-off
peptide may contain additional N-terminal amino acid
residues due to cloning. Proteases may also cleave at sites
different from the engineered cleavage site and destroy the
peptide of interest. In addition, the expenses for proteases
can account for a considerable portion of the production
costs of recombinant peptides. Chemical cleavage, e.g., by
CNBr at methionine residues placed between the fusion
partner and the peptide sequence, apart from requiring high
lab-safety standards, can also happen at other methionine
residues that may be in the peptide.
The production of peptides as fusion proteins with
inteins is a way to avoid potential problems with proteolytic
or chemical cleavage. Inteins are segments of proteins that
are able to excise themselves by a self-catalytic mechanism
and rejoin the two flanking parts, the N- and C-exteins,
with a peptide bond (Perler and Adam 2000; Saleh and
Perler 2006). This splicing reaction is typically initiated by
an N to S or N to O acyl shift of Cys1 or Ser1 at the N-
terminus of the intein. The resulting (thio)ester is attacked
by the first residue of the C-extein, leading via several
intermediates to the formation of a new peptide bond
between the exteins. For biotechnological purposes, mod-
ified inteins have been designed. For example, in the
pTWIN vectors (New England Biolabs), the N-terminal
cysteine of intein Ssp/ DnaB (Wu et al. 1998) has been
changed to alanine to block the splicing reaction. This
mutant intein is still able to undergo temperature and pH
dependent cleavage of the peptide bond between the C-
terminus of the intein and the downstream amino acid, thus
releasing the C-terminally fused target protein (Mathys et
al. 1999; Wood et al. 1999). The design of the multiple
cloning site downstream of the Ssp/ DnaB coding sequence
in the pTWIN vectors includes a SapI restriction site that
allows the attachment of the peptide sequence immediately
downstream of the intein splice site, thus not leaving any
additional N-terminal residues in the peptide after the splice
reaction. With such an N-terminal intein fusion construct,
recombinant Conk-S1 has been produced (Bayrhuber et al.
2006). The Ssp/D n a B –Conk-S1 fusion protein was
expressed in insoluble form and was refolded in a buffer
containing oxidized and reduced glutathione as oxido-
shuffling reagents (Bayrhuber et al. 2006). Cleavage of
the fusion protein was achieved by shift to lower pH (from
7.5 to 6.5) and incubation overnight at room temperature.
This type of expression construct was also successfully
used for the production of another recombinant conkunitzin
(unpublished results) and of recombinant Kaliotoxin (Lange
et al. 2006), a potassium channel inhibitor from the venom
of the scorpion Leiurus quinquestriatus.
In summary, the production of disulfide-bonded proteins
in E. coli frequently includes the refolding of these proteins
from inclusion bodies or secretion into the periplasmic
space. Both approaches tend to decrease the final yield. An
alternative to the production in E. coli is the production of
disulfide-bonded proteins in eukaryotic expression systems.
The methylotrophic yeast, Pichia pastoris, provides an
intracellular folding environment similar to mammalian
cells and secretion into the surrounding medium can be
easily accomplished (White et al. 1994). Using this
expression system, a number of highly disulfide-bonded
proteins have been produced (Kristensen et al. 1999; Cabral
et al. 2003). The level of secretion per cell is fairly low in P.
pastoris (White et al. 1994). Therefore, high-density
fermentation was originally a requirement to produce larger
amounts of secreted proteins. More recently, the coexpres-
sion of protein disulfide isomerase, which probably reduces
the retention of disulfide-bonded proteins in the endoplas-
6 Appl Microbiol Biotechnol (2008) 79:1–9mic reticulum, has led to enormous improvements of
expression yields also in less dense cultures (Vad et al.
2005; Tsai et al. 2006; Huo et al. 2007). Similar to E. coli,
P. pastoris requires no special equipment for handling and
the growth media are not more expensive than those for E.
coli. Thus, production of disulfide-bonded proteins in P.
pastoris has developed into an attractive alternative to
production in E. coli. But a successful production of
conopeptides has not been reported so far. Insect cells are
also used for the production of disulfide-bonded proteins
with the Baculovirus system (Vogel et al. 2004; Galesi et al.
2007). Stably transfected Drosophila melanogaster S2 cells
(Galesi et al. 2007) are another insect cell expression
system. Recently, psalmotoxin 1, an acid-sensing ion
channel inhibitor, was successfully produced in a stable
D. melanogaster S2 cell line (Escoubas et al. 2003). Due to
the high costs of insect cell media, a more wide-spread use
of insect cells for the production of highly disulfide-bonded
peptides is currently unlikely.
A central consideration of biotechnological protein
production is cost-effectiveness. Of all approaches de-
scribed here, production in E. coli is the least expensive
because of the very low costs for the culture media and the
low investments necessary for culturing these bacteria.
Thus, despite of the difficulties encountered, especially
with the production of highly disulfide-bonded proteins and
peptides like, e.g., the conopeptides, E. coli remains the
system of choice for their recombinant production. Only the
yeast, P. pastoris, having the advantage compared to E. coli
of providing an intracellular folding environment similar to
that of mammalian cells, provides an excellent alternative
to bacterial expression systems. Other eukaryotic expres-
sion systems like, e.g., insect cells or even mammalian cells
require prohibitively expensive culture media and expen-
sive cell culture equipment. Regarding the large group of
small conotoxins with posttranslational modifications, their
production is, at present, still mostly confined to chemical
synthesis, e.g., by SPPS. In vitro systems comprising
posttranslational modification enzymes to transform recom-
binant precursors into bioactive peptides have been suc-
cessfully used (Ozawa et al. 2007). But at present, they
offer no higher cost-effectiveness compared to the chemical
synthesis and may only be used in the future in cases where
refolding of chemically synthesized, highly disulfide-
bonded peptides with modified amino acids has not been
successful.
Altogether, for the majority of the presently known
conopeptides, chemical synthesis is the most important
method to produce large amounts of peptide. Recombinant
production remains confined to conopeptides without
posttranslational modifications. The rapid development of
these methods in recent years may allow the biosynthetic
production of some modified peptides in the future.
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